These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 7521667

  • 21. CD2 is a dominant target for allogeneic responses.
    Bai Y, Fu S, Honig S, Wang Y, Qin L, Chen D, Bromberg JS.
    Am J Transplant; 2002 Aug; 2(7):618-26. PubMed ID: 12201362
    [Abstract] [Full Text] [Related]

  • 22. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.
    Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP.
    J Exp Med; 1993 Jul 01; 178(1):211-22. PubMed ID: 7686212
    [Abstract] [Full Text] [Related]

  • 23. Homotypic cell to cell cross-talk among human natural killer cells reveals differential and overlapping roles of 2B4 and CD2.
    Kim EO, Kim TJ, Kim N, Kim ST, Kumar V, Lee KM.
    J Biol Chem; 2010 Dec 31; 285(53):41755-64. PubMed ID: 20813844
    [Abstract] [Full Text] [Related]

  • 24. Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat.
    Sido B, Otto G, Zimmermann R, Müller P, Meuer S, Dengler TJ.
    Transpl Int; 1996 Dec 31; 9 Suppl 1():S323-7. PubMed ID: 8959856
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Enhanced murine CD4+ T cell responses induced by the CD2 ligand CD48.
    Latchman Y, Reiser H.
    Eur J Immunol; 1998 Dec 31; 28(12):4325-31. PubMed ID: 9862369
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Human b cell differentiation: dependence on interactions with monocytes and T lymphocytes via CD40, CD80 (B7.1), and the CD2-Ligands CD48 and CD58 (LFA-3).
    Hoffmann JC, Krüger H, Zielen S, Bayer B, Zeidler H.
    Cell Biol Int; 1998 Dec 31; 22(1):21-9. PubMed ID: 9828079
    [Abstract] [Full Text] [Related]

  • 31. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
    Kwekkeboom J, de Rijk D, Kasran A, Barcy S, de Groot C, de Boer M.
    Eur J Immunol; 1994 Mar 31; 24(3):508-17. PubMed ID: 7510232
    [Abstract] [Full Text] [Related]

  • 32. Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen.
    Koyasu S, Lawton T, Novick D, Recny MA, Siliciano RF, Wallner BP, Reinherz EL.
    Proc Natl Acad Sci U S A; 1990 Apr 31; 87(7):2603-7. PubMed ID: 1690889
    [Abstract] [Full Text] [Related]

  • 33. CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.
    Menu E, Tsai BC, Bothwell AL, Sims PJ, Bierer BE.
    J Immunol; 1994 Sep 15; 153(6):2444-56. PubMed ID: 7521361
    [Abstract] [Full Text] [Related]

  • 34. Monoclonal antibodies anti-CD3, anti-TCR alpha beta and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon gamma.
    Chong AS, Staren ED, Scuderi P.
    Cancer Immunol Immunother; 1992 Sep 15; 35(5):335-41. PubMed ID: 1382856
    [Abstract] [Full Text] [Related]

  • 35. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
    Valentin H, Groux H, Gelin C, Chretien I, Bernard A.
    J Immunol; 1990 Feb 01; 144(3):875-82. PubMed ID: 1967277
    [Abstract] [Full Text] [Related]

  • 36. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2.
    Lin J, Yon RW, Chavin KD, Qin L, Woodward J, Ding Y, Yagita H, Bromberg JS.
    Transplantation; 1995 Apr 27; 59(8):1162-71. PubMed ID: 7537394
    [Abstract] [Full Text] [Related]

  • 37. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
    Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, Prentice HG, Hazlehurst G, Hoffbrand AV.
    Blood; 1991 May 01; 77(9):1996-2001. PubMed ID: 1708296
    [Abstract] [Full Text] [Related]

  • 38. Production and characterization of soluble and transmembrane murine CD2. Demonstration that CD48 is a ligand for CD2 and that CD48 adhesion is regulated by CD2.
    Kaplan AJ, Chavin KD, Yagita H, Sandrin MS, Qin LH, Lin J, Lindenmayer G, Bromberg JS.
    J Immunol; 1993 Oct 15; 151(8):4022-32. PubMed ID: 8104993
    [Abstract] [Full Text] [Related]

  • 39. Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.
    Van de Wiel-van Kemenade E, Te Velde AA, De Boer AJ, Weening RS, Fischer A, Borst J, Melief CJ, Figdor CG.
    Eur J Immunol; 1992 Jun 15; 22(6):1467-75. PubMed ID: 1376259
    [Abstract] [Full Text] [Related]

  • 40. The role of CD2/LFA-3 interaction in antigen- and mitogen-induced activation of human T cells.
    Tiefenthaler G, Hünig T.
    Int Immunol; 1989 Jun 15; 1(2):169-75. PubMed ID: 2484882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.